Loading
CALLA tested adding the PD-L1 antibody durvalumab to chemoradiotherapy for locally advanced cervical cancer and found no significant benefit, in contrast to the later positive KEYNOTE-A18 trial of pembrolizumab in a higher-risk population.
CALLA randomised 770 women with locally advanced cervical cancer (FIGO 2009 stage IB2 to IIB node-positive, or III to IVA) to durvalumab or placebo given with cisplatin-based external beam radiotherapy and brachytherapy and continued for up to 24 cycles. The primary endpoint was progression-free survival.
Durvalumab did not significantly improve progression-free survival, though exploratory analyses suggested benefit in tumours with high PD-L1 expression. KEYNOTE-A18, which enrolled a higher-risk population and used pembrolizumab, reported a positive result the following year, and the reasons for the difference (population, agent, radiotherapy quality) are debated.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
770 enrolled.
Not reached; median follow-up 18.5 months · Not reached
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (investigator-assessed)primary | Durvalumab + chemoradiotherapy | 385 | Not reached; median follow-up 18.5 months | 0.84 (0.65 to 1.08) | 0.17 | link |
| Placebo + chemoradiotherapy | 385 | Not reached | ||||
| Progression-free survival at 12 months | Durvalumab + chemoradiotherapy | 385 | 76% | - | - | link |
| Placebo + chemoradiotherapy | 385 | 73.3% | ||||
| Serious adverse events | Durvalumab + chemoradiotherapy | 385 | 28% | - | - | link |
| Placebo + chemoradiotherapy | 384 | 23% |
Shares Durvalumab, AstraZeneca, Cisplatin, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Cisplatin, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Cervical cancer, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Cisplatin, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Cisplatin, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Cisplatin and the tag subtype-trials.
Shares Cervical cancer and the tag subtype-trials.
Shares Immune checkpoint inhibitors and the tag subtype-trials.